Metastatic Osteosarcoma Treatment Market - Global
Industry Insights, Trends, and Opportunity Analysis
2018–2026
Osteosarcoma or bone cancer is a type of cancer were bone tissues show an abnormal growth.
Osteosarcoma that spreads from initially affected area to distant site is known as metastatic
osteosarcoma. Metastatic osteosarcoma often spreads to lungs, whereas less commonly spreads
to other bones, brain or other organs. Symptoms of metastatic osteosarcoma varies based on the
location of tumor, for example bone pain, bone fracture, swelling, redness, limping, and limited
joint movement. If the tumor spreads to the lungs the symptoms include chest pain, shortness
of breath, cough with blood, chronic coughing or wheezing. Diagnostic tests for metastatic
osteosarcoma includes CT-scan, MRI, X-ray, PET scan, biopsy, and bone scan. Treatment of
metastatic osteosarcoma involves surgery, radiation, chemotherapy, biological therapy or a
combination of these treatments. Combinational treatment also known as multi-modality
treatment is more preferred by medical practitioners to increase treatment outcomes or to
prolong survival.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1578
Metastatic Osteosarcoma Treatment Market – Drivers
Increasing drug pipeline for malignant bones and soft tissue (Ewing Sarcoma) cancer is expected
to drive growth of metastatic osteosarcoma treatment market. For instance, in 2017, Merck &
Co., Inc., studies the effects of Pembrolizumab (MK-3475) in patients with relapsed or
metastatic osteosarcoma and reported that these patient are not eligible for curative surgery.
Currently, study is in phase II clinical trial and is expected to be marketed in 2023. Moreover,
Novartis entered into phase II clinical trials for pazopanib for treatment of metastatic
osteosarcoma as of March 2018.
Emerging new therapies for metastatic osteosarcoma treatment will further propel growth of the
market. For instance, clinical trials for immunotherapy-based drugs and targeted drug therapy is
expected to be a preferred option in the near future, owing to less side-effects. The immune